ADC is a novel anti-cancer drug consisting of a monoclonal antibody coupled with a cytotoxic drug via chemical linker.598 ZIP6 is the cell surfacing target that is critical in cancer progression, which is undoubtedly the best candidate for ADC therapy.599,600 As a result, inhibitors of ZIP6, a promising target, are being developed. The gene discussed is SLC39A6; the disease is cancer.